Abstract: The invention provides a new polymorph of 1-(2-methyl-4-(2,3,4,5-tetrahydro-1-benzazepin-1-ylcarbonyl)benzyl-carbamoyl)-L-proline-N,N-dimethylamide, pharmaceutical compositions containing it and its use in therapy.
Type:
Grant
Filed:
March 31, 2011
Date of Patent:
July 14, 2015
Assignee:
Vantia Limited
Inventors:
Kjellström Henrik Johan, Johansson Erik Björn, Vilhelmsen Thomas
Abstract: The invention provides cyclopropanecarboxylic acid 4-(6-chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraazabenzo[f]azulene-9-carbonyl)-2-fluoro-benzylamide para-toluenesulphonate, pharmaceutical compositions containing it, and its use in therapy.
Type:
Grant
Filed:
March 18, 2011
Date of Patent:
July 7, 2015
Assignee:
Vantia Limited
Inventors:
Andrzej Roman Batt, Rachel Louisa Charlotte Handy, Michael Bryan Roe, Valerie Elizabeth Peal, Timothy John Kenhardt Gibs, David Raymond Churchley
Abstract: The invention provides a new polymorph of 1-(2-methyl-4-(2,3,4,5-tetrahydro-1-benzazepin-1-ylcarbonyl)benzyl-carbamoyl)-L-proline-N,N-dimethylamide, pharmaceutical compositions containing it and its use in therapy.
Type:
Application
Filed:
March 31, 2011
Publication date:
October 2, 2014
Applicant:
VANTIA LIMITED
Inventors:
Kjellstrom Henrik Johan, Johansson Erik Björn, Vilhelmsen Thomas
Abstract: The present invention concerns compounds inter alia according to general formula 1a. Compounds according to the invention are vasopressin V1a receptor antagonists. Pharmaceutical compositions of the compounds are useful as treatment of dysmenorrhoea.
Type:
Grant
Filed:
August 24, 2005
Date of Patent:
June 19, 2012
Assignee:
Vantia Limited
Inventors:
Andrzej Roman Batt, Martin Lee Stockley, Michael Bryan Roe, Celine Marguerite Simone Heeney, Andrew John Baxter, Peter Hudson, Rachel Handy
Abstract: The present invention provides compounds of formula (1) compositions comprising such compounds; the use of such compounds in therapy (such as in the treatment of dysmenorrhoea); and methods of treating patients with such compounds; wherein A and G are as defined herein.
Type:
Application
Filed:
February 25, 2010
Publication date:
December 22, 2011
Applicant:
VANTIA LIMITED
Inventors:
Andrzej Roman Batt, Celine Marguerite Simone Heeney
Abstract: The invention concerns compounds according to general formulae 1, wherein G1 is an amine. Compounds according to the invention are vasopressin V2 receptor agonists. Pharmaceutical compositions of the compounds are useful as antidiuretic agents.
Abstract: The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (such as asthma or COPD); and methods of treating patients with such compounds; wherein R1-R11 are as defined herein.
Type:
Application
Filed:
April 28, 2009
Publication date:
March 25, 2010
Applicant:
VANTIA LIMITED
Inventors:
David Michael Evans, Christine Elizabeth Allan, John Horton, David Philip Rooker
Abstract: Compounds of general formula 1, or a pharmaceutically acceptable salt thereof, wherein R1 is selected from H, lower alkyl, R4—CO, R4—O2CCH2, R5—OCO and R5—SO2; R2 is selected from lower alkyl, cycloalkyl optionally substituted with an alkyl or alkyloxy group, (C5-C12)cycloalkylalkyl optionally substituted with an alkyl or alkyloxy group, aralkyl optionally substituted with up to three groups chosen from F, Cl, Br, I, OH, lower alkyl, O-(lower alkyl), O-benzyl, NH2, NO2, NH-acyl, CN and CF3, and aralkyloxymethyl optionally substituted with up to three groups chosen from F, Cl, Br, OH, lower alkyl and O-(lower alkyl); or R1 and R2 together are an o-xylylene group optionally substituted on the aromatic ring with a group selected from F, Cl, Br, OH, lower alkyl and O-(lower alkyl); R3 is selected from H, OH and O-lower alkyl; R4 is selected from H, lower alkyl and phenyl; and R5 is selected from lower alkyl, phenyl and benzyl. The compounds are useful as pharmaceutical compositions.
Abstract: This invention provides novel compounds according to general formula (1) wherein A is a bicyclic or tricyclic azepine derivative, V1 and V2 are both H, OMe or F, or one of V1 and V2 is Br, Cl, F, OH, OMe, OBn, OPh, O-acyl, N3, NH2, NHBn or NH-acyl and the other is H, or V1 and V2 together are ?O, —O(CH2)pO— or —S(CH2)pS—; W1 is either O or S; X1 and X2 are both H, or together are ?O or ?S; Y is OR5 or NR6R7; R1, R2, R3 and R4 are independently selected from H, lower alkyl, lower alkyloxy, F, Cl and Br; R5 is selected from H and lower alkyl; R6 and R7 are independently selected from H and lower alkyl, or together are —(CH2)n—; n=3, 4, 5, 6; and p is 2 or 3. The compounds are agonists at the vasopressin V2 receptor and are useful as antidiuretics and procoagulants. The invention further comprises pharmaceutical compositions incorporating these vasopressin agonists, which compositions are particularly useful in the treatment of central diabetes insipidus, nocturnal enuresis and nocturia.
Type:
Grant
Filed:
March 9, 2006
Date of Patent:
July 14, 2009
Assignee:
Vantia Limited
Inventors:
Doreen Mary Ashworth, Gary Robert William Pitt, Peter Hudson, Christopher Martyn Yea, Richard Jeremy Franklin